-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Article source: Medical Rubik's Cube Info
Author: Sunshine
On November 24, the website of the China Clinical Trial Registration Center showed that Watson Bio-registered an evaluation of the new coronavirus mRNA vaccine (ARCoVaX) in 18-59 years old and 60 years old and above who have been vaccinated with the new coronavirus inactivated vaccine.
ARCoVaX is an mRNA vaccine jointly developed by Abbio, Watson Bio and the Academy of Military Medicine to prevent new coronary pneumonia caused by SARS-CoV-2 infection
According to the information disclosed by Abbio, the protection rate of ARCoVaX is equivalent to that of the marketed vaccine.
On May 11, 2020, Watson Biotech and Abbio signed the "Technology Development Cooperation Agreement" to jointly develop the new coronavirus mRNA vaccine research and development and commercial production